p. 35−36
2383-4544
Vol.5/No.2
p. 37−40
2383-4544
Vol.5/No.2
p. 41−46
2383-4544
Vol.5/No.2
5. Data such as demographic information, signs and symptoms, medical history, risk factors, focused neurological examination, and the NIHSS were collected for all patients. Then, all patients received 0.9 mg/kg of rt-PA as intravenous bolus doses and intravenous infusion under close monitoring in the emergency department. All patients were checked for necessary outcomes and also disability at the admission time, 7 days later and after three months all patients were checked again. All collected data were analyzed by appropriate tests using SPSS version 22.Results: Of all patients, 63.3% were males and 36.7% were females. The mean age of the patients was 62.37 ± 12.62 years with a range of 40-91 years. The mean of NIHSS was 12.46 ± 4.28 at admission time, in day seven it was 8.06 ± 3.72 and in month three after treatment it was 3.62 ± 2.31. There was a significant relationship between age, place of residence and NIHSS. Thirty percent of patients had NIHSS more than 15 at admission time and after 7 days this rate reached to 10% and three months later it declined to 6.7%. These differences were statistically significant.Conclusion: Intravenous thrombolytic therapy is associated with proper short term results in most patients with ischemic stroke.]]>
p. 47−50
2383-4544
Vol.5/No.2
p. 51−55
2383-4544
Vol.5/No.2
p. 56−60
2383-4544
Vol.5/No.2
p. 61−64
2383-4544
Vol.5/No.2
p. 65−70
2383-4544
Vol.5/No.2
p. 71−74
2383-4544
Vol.5/No.2
p. 75−77
2383-4544
Vol.5/No.2
p. 78−80
2383-4544
Vol.5/No.2
p. 81−84
2383-4544
Vol.5/No.2